Cinacalcet Intermediates N-((R)-1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoroMethyl)phenyl)propanamide CAS 1005450-55-4

Basic Info

Model No.: 1005450-55-4

Additional Info

Packaging: AS REQUIRED

Productivity: G,KGS,

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: COMMERCIAL PRODUCTION

Certificate: GMP/ISO

Product Description

N-((R)-1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoroMethyl)phenyl)propanamide is the chemical name of Cinacalcet HCl Intermediates CAS 1005450-55-4. Cinacalcet as a calcimimetic drug widely used to treatment of hypercalcemia in patients with parathyroid carcinoma. The Cinacalcet HCl Intermediates CAS NO 1005450-55-4, supplied by us, is high purity, precise formulation and stability. We keep certain inventory and can meet bulk production requirements of the customers

• Thera. Category: Anti-Hyperparathyroidism
• Cas No.: 226256-56-0
• Synonym: N-((R)-1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoroMethyl)phenyl)propanaMide;(R)-N-(1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoroMethyl)phenyl)propanaMide;N-[1-(R)-(1-Naphthyl)ethyl]-3-[3-trifluoroMethylphenyl]propanaMide;lN-((R)-1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoroMethyl)phenyl)propanaMide
• Molecular Formula: C22H22F3N

• 
  
• Molecular Weight: 371.3955096
• Specifications: Available on request
• Packing: Export worthy packing
• Material Safety Data Sheet: Available on request

Usage: Cinacalcet(AMG-073) is an orally active, second-generation calcimimetic compound; AMG 073 represents a new class of compounds for the treatment of hyperparathyroidism.Cinacalcet is the only calcimimetic approved for HPT secondary to chronic kidney disease (CDK), parathyroid carcinoma, and, in some countries, primary HPT. Clinical trials showed that cinacalcet reduced PTH and calcemia both in CDK and primary HPT, lowering the risk of bone fractures, surgery, and cardiovascular complications in the former patients. Long-term safety and pharmacoeconomics have to be fully tested yet. Few both in vitro and in vivo studies showed an association between Arg990Gly-CASR polymorphism and cinacalcet sensitivity, though in patients with severe CASR inactivating mutations the drug substantially retained its positive clinical effects.